Peter C. Farrell, who serves on the board of ResMed Inc (NYSE:RMD), executed a sale of 2,000 shares of the company's common stock on April 1, 2026, according to a Form 4 filed with the Securities and Exchange Commission. The shares were sold at $225.00 apiece, producing a total transaction value of $450,000.
The sale was carried out under a Rule 10b5-1 trading plan that Farrell adopted on August 12, 2025. After completing the transaction, Farrell's direct holdings in ResMed stand at 60,773 shares.
At the time of reporting, ResMed's stock price was quoted at $223.05. InvestingPro's Fair Value assessment lists ResMed among opportunities on its Most Undervalued stocks list, indicating the company appears undervalued by that analysis.
Company fundamentals cited by InvestingPro
InvestingPro assigns ResMed a "GREAT" financial health score and notes that the company has increased its dividend for 14 consecutive years. The platform also provides eight additional ProTips for investors in RMD.
Recent financial performance and analyst reactions
ResMed reported second-quarter fiscal 2026 earnings with diluted earnings per share of $2.81, topping consensus expectations of $2.73. Revenue for the quarter was $1.4 billion, matching analyst forecasts.
Several sell-side firms updated their views following the results. RBC Capital highlighted double-digit revenue and earnings growth and raised its price target for ResMed from $311 to $314 while maintaining an Outperform rating. KeyBanc Capital Markets also raised its price target, to $302 from $299, and kept an Overweight rating.
Other firms took a more cautious stance. Needham reiterated a Hold rating after the company reported 8% organic revenue growth in the second quarter, up from 7% in the prior quarter. Stifel maintained a Hold rating as well, with a price target of $265, citing findings from a proprietary survey of CPAP users.
These varied analyst responses reflect a mix of optimism tied to recent financial results and continued caution among some research teams.
What we know and what remains limited
The filing documents and company results provide clear, specific data on the insider sale, ownership after the trade, and recent quarterly performance. The InvestingPro commentary and ratings cited provide additional context regarding perceived valuation and company financial health. Where information is limited is in any explanation of Farrell's motives for the sale beyond the fact it was executed under a pre-established 10b5-1 plan; no further rationale is provided in the filings.